Latest Hospitality News

Neurotech International has opened the first clinical site for its pivotal Phase 3 trial of NTI164, targeting core symptoms of Autism Spectrum Disorder in children. This milestone marks a key step toward potential regulatory approval and commercialisation.

InteliCare Holdings has appointed seasoned healthcare executive Angus Cameron as CEO to lead its transition from pilot projects to full-scale commercial deployment following a major aged care contract.

BlinkLab has completed onboarding its tenth and final clinical site for its pivotal FDA 510(k) trial of an AI-powered autism diagnostic aid, setting the stage for patient enrolment to begin this month.

EMVision Medical Devices has secured a $3.8 million R&D tax rebate and gained approval to claim rebates on overseas expenditures, strengthening its financial footing as it advances clinical trials for its neurodiagnostic device.

Vection Technologies has secured approximately $4 million in new orders for its Algho AI platform, spanning 10 diverse industry verticals and reinforcing its strong momentum following a record half-year performance.

OMG Group has launched two new matcha brands targeting both premium and mass-market consumers, supported by a five-year exclusive supply agreement for ceremonial-grade Japanese matcha. This move positions OMG to capitalise on the booming global matcha market through a vertically integrated strategy.

Patrys has initiated manufacturing and regulatory steps for RLS-2201, its injectable Quetiapine formulation targeting delirium, aiming for Phase 0 trials in the second half of 2026.

Orthocell has appointed LEDA Orthopaedics as the exclusive distributor for its Remplir™ nerve repair product in the UK, positioning itself for a rapid commercial launch pending regulatory approval.

A new clinical study from Sichuan University confirms that TruScreen’s AI-enabled cervical cancer screening combined with high-risk HPV testing outperforms traditional cytology methods, reinforcing its global potential.

Endeavour Group reported a solid first half for fiscal 2026 with underlying EBIT of $563 million, supported by retail price leadership and strong hotel sales growth. The group raised capital expenditure guidance, reflecting accelerated hotel renewals and strategic investments.

Argent BioPharma reported a significantly reduced half-year loss of A$2.9 million, progressing a strategic acquisition to bolster its CannEpil drug pipeline and securing up to A$11 million in new funding.

Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.